Oncofocus
  • Services
    • Primary Market Research
    • Competitive Intelligence
  • About
  • Blog
  • Reports
  • Careers
  • Contact
“So it is said that if you know your enemies and know yourself, you can win a hundred battles without a single loss.
​If you only know yourself, but not your opponent, you may win or may lose.
​If you know
neither yourself nor your enemy, you will always endanger yourself.”
​- Sun Tzu from Art of War

Multiple Myeloma Indication

19/11/2019

 

BCMA CAR-T Pipeline Landscape ​

B-cell Maturation Antigen (BCMA) as an antigen has been shown to be specifically expressed in myeloma cells. With the ASH Annual Meeting 2019 close at hand, we performed a comprehensive pipeline analysis of BCMA targeting CAR-Ts in Multiple Myeloma indication.
Picture
Read More

Melanoma Indication

29/10/2019

 

PD-1/PD-L1 Combination Strategies

​Malignant melanoma is a complex, multifactorial disease, which is responsible for up to 75% of skin cancer related deaths globally.

With the US FDA approval of ipilimumab (CTLA-4 targeting agent) in 2011 for the treatment of advanced melanoma patients, clinical research intensity has gradually shifted towards Immune Checkpoint Inhibitors (ICIs) & their Combination agents. 

After the approval of nivolumab and pembrolizumab (both are PD-1 targeting agents), it is imperative to understand how PD-1/PD-L1 clinical landscape is evolving in melanoma.
​
Picture
Read More

Small Cell Lung Cancer Indication

18/9/2019

0 Comments

 

Immune Checkpoint Inhibitors (ICIs) Pipeline Landscape

SCLC is an unforgiving, highly aggressive variant of lung cancer. It accounts for approximately 15% of the lung cancer cases globally and is also a major cause of cancer-related deaths. ​The chemotherapy has been the mainstay in SCLC management. While response rate to chemotherapy is high, notably, almost all patients relapse after few months (PFS is typically 4.0 - 5.5 months).
Picture
Read More
0 Comments

All

8/4/2019

 

CAR-T Clinical Landscape Report

A lot has happened in the CAR-T field in the past 10 months since our last conference report on this technology. These include high-impact news such as EMA approval, and NICE recommendations for Kymriah and Yescarta.

As the ASCO 2019 Annual Meeting is less than a month away, we are publishing an updated CAR-T clinical landscape report. This year, in addition to updating the industry funded CAR-T pipeline, we have included non-industry funded CAR-Ts, as well. We believe this addition will give you a better picture of the current CAR-T clinical landscape. To keep the scope manageable, we have limited our research to only those CAR-Ts that are conducted in US and/or EU location(s).

We hope this report will help you get up to speed before the upcoming ASCO 2019 Annual Meeting.
Picture
Read More

Cervical Cancer

8/8/2017

 

Cervical Cancer Screening Awareness Survey (Focus: India)

We are pleased to announce that our research work on Cervical Cancer Awareness in India has been accepted by the ESMO Scientific Committee. The study has been published as an abstract in ESMO 2017. 
Are you aware of Cervical cancer?
​
Picture
Do you know that Cervical cancer is preventable by regular screening? 
Picture
Did you get yourself or your family members tested for Cervical cancer?
Picture
Read More

    Categories

    All
    BCMA
    CARTs
    Cervical Cancer
    Melanoma
    Multiple Myeloma
    PD-1 And PD-L1
    Pipeline Landscape

    Archives

    November 2019
    October 2019
    September 2019
    April 2019
    August 2017

Bangalore Office
Oncofocus Solutions Pvt Ltd, 

#4, II Floor, 5th Main, 9th Cross, Jaya Mahal Ext,
Bengaluru
, India 56 00 46

Tel. +91 89044 00482

E-mail: support@oncofocus.com
RFQ: rfq@oncofocus.com
​

Singapore Office (Sales)
Oncofocus Solutions Pte Ltd, 

51 Goldhill Plaza, 
#07-10/11
​Singapore 30 89 00
​



E-mail: support@oncofocus.com.sg
​RFQ: rfq@oncofocus.com
​

    Subscribe to our Newsletter

Subscribe to Newsletter
Tweets by oncofocus
  • Services
    • Primary Market Research
    • Competitive Intelligence
  • About
  • Blog
  • Reports
  • Careers
  • Contact